Abstract:Variation in blood pressure levels display circadian rhythms. Complete 24‐hour blood pressure control is the primary goal of antihypertensive treatment and reducing adverse cardiovascular outcomes is the ultimate aim. This is an update of the review first published in 2011. To evaluate the effectiveness of administration‐time‐related effects of once‐daily evening versus conventional morning dosing antihypertensive drug therapy regimens on all‐cause mortality, cardiovascular mortality and morbidity, total adverse events, withdrawals from treatment due to adverse effects, and reduction of systolic and diastolic blood pressure in people with primary hypertension. We searched the Cochrane Hypertension Specialised Register via Cochrane Register of Studies (17 June 2022), Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 6, 2022); MEDLINE, MEDLINE In‐Process and MEDLINE Epub Ahead of Print (1 June 2022); Embase (1 June 2022); ClinicalTrials.gov (2 June 2022); Chinese Biomedical Literature Database (CBLD) (1978 to 2009); Chinese VIP (2009 to 7 August 2022); Chinese WANFANG DATA (2009 to 4 August 2022); China Academic Journal Network Publishing Database (CAJD) (2009 to 6 August 2022); Epistemonikos (3 September 2022) and the reference lists of relevant articles. We applied no language restrictions. We included randomised controlled trials (RCTs) comparing the administration‐time‐related effects of evening with morning dosing monotherapy regimens in people with primary hypertension. We excluded people with known secondary hypertension, shift workers or people with white coat hypertension. Two to four review authors independently extracted data and assessed trial quality. We resolved disagreements by discussion or with another review author. We performed data synthesis and analyses using Review Manager Web for all‐cause mortality, cardiovascular mortality and morbidity, serious adverse events, overall adverse events, withdrawals due to adverse events, change in 24‐hour blood pressure and change in morning blood pressure. We assessed the certainty of the evidence using GRADE. We conducted random‐effects meta‐analysis, fixed‐effect meta‐analysis, subgroup analysis and sensitivity analysis. We included 27 RCTs in this updated review, of which two RCTs were excluded from the meta‐analyses for lack of data and number of groups not reported. The quantitative analysis included 25 RCTs with 3016 participants with primary hypertension. RCTs used angiotensin‐converting enzyme inhibitors (six trials), calcium channel blockers (nine trials), angiotensin II receptor blockers (seven trials), diuretics (two trials), α‐blockers (one trial), and β‐blockers (one trial). Fifteen trials were parallel designed, and 10 trials were cross‐over designed. Most participants were white, and only two RCTs were conducted in Asia (China) and one in Africa (South Africa). All trials excluded people with risk factors of myocardial infarction and strokes. Most trials had high risk or unclear risk of bias in at least two of several key criteria, which was most prominent in allocation concealment (selection bias) and selective reporting (reporting bias). Meta‐analysis showed significant heterogeneity across trials. No RCTs reported on cardiovascular mortality and cardiovascular morbidity. There may be little to no differences in all‐cause mortality (after 26 weeks of active treatment: RR 0.49, 95% CI 0.04 to 5.42; RD 0, 95% CI −0.01 to 0.01; very low‐certainty evidence), serious adverse events (after 8 to 26 weeks of active treatment: RR 1.17, 95% CI 0.53 to 2.57; RD 0, 95% CI −0.02 to 0.03; very low‐certainty evidence), overall adverse events (after 6 to 26 weeks of active treatment: RR 0.89, 95% CI 0.67 to 1.20; I2 = 37%; RD −0.02, 95% CI −0.07 to 0.02; I2 = 38%; very low‐certainty evidence) and withdrawals due to adverse events (after 6 to 26 weeks active treatment: RR 0.76, 95% CI 0.47 to 1.23; I2 = 0%; RD −0.01, 95% CI −0.03 to 0; I2 = 0%; very low‐certainty evidence), but the evidence was very uncertain. Due to the very limited data and the defects of the trials' designs, this systematic review did not find adequate evidence to determine which time dosing drug therapy regimen has more beneficial effects on cardiovascular outcomes or adverse events. We have very little confidence in the evidence showing that evening dosing of antihypertensive drugs is no more or less effective than morning administration to lower 24‐hour blood pressure. The conclusions should not be assumed to apply to people receiving multiple antihypertensive drug regimens. Key messages — There may be little to no difference in death for any reason between taking blood pressure‐lowering medicines in the morning or evening, but we have no confidence in the results. The difference in unwanted effects was not known. — Taking blood pressure‐lowering medicines in the evening may give slightly better bl -Abstract Truncated-

Management of morning hypertension: a consensus statement of an Asian expert panel

The HOPE Asia network 2022 up-date consensus statement on morning hypertension management

Management of nocturnal hypertension: An expert consensus document from Chinese Hypertension League

Evening dosing versus morning dosing of antihypertensive medications for nocturnal hypertension: a systematic review and meta-analysis of 107 randomized controlled trials

Comparative Analysis of Hypertension Guidelines: Unveiling Consensus and Discrepancies in Lifestyle Modifications for Blood Pressure Control

Morning hypertension is more common in elderly hypertensive patients with controlled documented office blood pressure in primary care clinics: the Minhang study

Differential Effects of Morning or Evening Dosing of Amlodipine on Circadian Blood Pressure and Heart Rate

Clinical significance of nocturnal home blood pressure monitoring and nocturnal hypertension in Asia

Guidance on ambulatory blood pressure monitoring: A statement from the HOPE Asia Network

Current Status of Morning Blood Pressure Control and Medication of Hypertensive Patients in Beijing

Guidance on home blood pressure monitoring: A statement of the HOPE Asia Network

Ambulatory blood pressure monitoring profiles in Asia

Management of Hypertension in the Asia-Pacific Region: A Structured Review

Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension

Expert Consensus on the Management of Hypertension in the Young and Middle-Aged Chinese Population

Evening versus morning dosing regimen drug therapy for hypertension

The Influence of Combined Bisorpolol/hydrochlorothiazide on Morning Blood Pressure Surge in Mild to Moderate Essential Hypertension

Reduction of the Morning Blood Pressure Surge Treated with Olmesartan in Chinese Patients with Mild to Moderate Essential Hypertension - A Multicenter, Open-Label, Single Treatment Group Clinical Study

Home blood pressure-centered approach - from digital health to medical practice: HOPE Asia Network consensus statement 2023

Asian management of hypertension: Current status, home blood pressure, and specific concerns in India

Asian management of hypertension: Current status, home blood pressure, and specific concerns in Malaysia